Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-03-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subarachnoid haemorrhage (SAH) may cause damage to the hypotalamo-pituitary-adrenal axis (HPA) thus disturbing the hormonal response of these structures.

The aim of our study is to characterize the function of HPA-axis acutely and over time up to three months in patients with SAH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endocrine Dysfunction and Quality of Life After Subarachnoid Hemorrhage

NCT01101711

Endocrine Dysfunction Cerebral Infarctions Quality of Life

COMPLETED

Hypopituitarism After Aneurismal Subarachnoid Hemorrhage

NCT00962559

Aneurismal Subarachnoid Hemorrhage Hypopituitarism Neuropsychological Deficits

COMPLETED

Searching a Dysfunction of Corticotropic & Thyrotropin Axis During the Acute Phase of a Subarachnoid Hemorrhage Secondary to Spontaneous Rupture of Cerebral Aneurysm

NCT03655509

Subarachnoid Hemorrhage

UNKNOWN NA

Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage

NCT02915380

Thyroid Disfunction Subarachnoid Haemorrhage From Cerebral Aneurism Rupture Pituitary Disfunction

UNKNOWN

Constitution of Cerebrospinal Fluid and Blood Database/Specimen in Acute Stage of Subarachnoid Hemorrhage (aSAH) Patients

NCT01292278

Subarachnoid Hemorrhage

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The hypotalamo-pituitary-adrenal (HPA)-axis may be affected in SAH by temporary or permanent damage to the hypothalamus and/or pituitary gland. Also surgery or endovascular treatment of a ruptured intracranial aneurysm may affect the hormonal response of the HPA-axis. Some data suggest a high incidence of delayed endocrine abnormalities in patients with SAH but only little data exists on the acute endocrine abnormalities in this disease.

We will study the pituitary-adrenal hormone levels in patients with acute aneurysmal SAH and patients admitted for elective cranial aneurysm surgery will serve as a control population. We will use serum free cortisol calculation and total cortisol measurements as well as adrenocorticotrophic hormone (ACTH) stimulation test in assessing the responsiveness of the adrenal gland to exogenous ACTH. The hormone levels will be measured repeatedly during the first seven days after SAH and once at three months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subarachnoid Hemorrhage Cerebral Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2

Patients scheduled for elective cerebral aneurysmal surgery

No interventions assigned to this group

1

Patients with subarachnoid hemorrhage

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

SAH-group:

* \>age 18,
* Subarachnoid hemorrhage due to an cerebral aneurysm

Control group:

* Age \>18
* Admitted for elective primary cerebral aneurysm surgery

Exclusion Criteria

SAH group:

* Any corticoid treatment (also inhaled)
* Usage of etomidate before study entry or during the study period
* Exact bleeding day unknown
* Previous history of SAH or more than three days of current bleeding
* Previous aneurysm surgery or embolization
* Traumatic SAH
* Known pituitary insufficiency and moribund state of the patient
* Refusement of the patient

control group:

* Any corticoid treatment (also inhaled)
* Usage of etomidate before study entry or during the study period
* Previous history of SAH or cerebral aneurym surgery or embolization
* Admitted for elective aneurysm embolization
* Known pituitary insufficiency
* Refusement of the patienT

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No